Torrey Pines Therapeutics said today that the FDA has agreed to let it conduct a final-stage clinical trial of tezempanel for acute migraine headaches. The pivotal trial will examine tezempanel at a 40 milligram and a lower dose, while also monitoring patients for any heart irregularities known as QT prolongation. The timing of the trial will depend on when the La Jolla, CA-based company (NASDAQ: [[ticker:TPTX]]) can find a partner or raise cash.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
